Prefilled syringes have evolved from relatively simple primary containers into increasingly sophisticated drug-delivery systems. They may be used manually, fitted with safety devices or incorporated into autoinjectors. They are now expected to deliver larger volumes and higher-viscosity biologic formulations, often in a patient’s home.
ISO 11040-8:2026 reflects this changing landscape. Published in June 2026, the second edition replaces ISO 11040-8:2016 and places greater emphasis on evaluating the finished prefilled syringe as a complete system under conditions representative of its intended use.
What is ISO 11040?
ISO 11040 is a series of international standards governing prefilled syringes and their components. Different parts of the series address areas such as glass and plastic syringe barrels, plunger stoppers and ready-for-filling subassemblies.
Part 8 focuses on the finished prefilled syringe. It addresses quality, functional performance and safety requirements, together with the associated test methods.
The standard applies to single-use, aseptically processed or terminally sterilized prefilled syringes based on barrels covered by ISO 11040-4 or ISO 11040-6, with plunger stoppers covered by ISO 11040-5. It can also provide guidance for other formats, including dual-chamber syringes.
This distinction between components and finished products is important. A barrel, stopper and closure may each meet their individual specifications, but the assembled and filled syringe must still function safely and reliably as a system. The drug formulation, filling process, sterilization method, storage conditions and any attached or associated delivery device can all affect performance.
ISO 11040-8 therefore considers the syringe in two roles:
- As a container-closure system that protects the pharmaceutical product
- As a delivery device that enables the dose to be administered safely and effectively
For syringes used in needle-based injection systems such as autoinjectors, ISO 11608 should also be considered.
What was revised?
ISO 11040-8:2026 is the second edition of the standard and replaces the first edition published in 2016. It is a technical revision, but not a complete reinvention of the standard. Many familiar performance characteristics remain. The biggest change is the stronger connection between intended use, risk management and the selection of representative test conditions.
The official foreword identifies revisions across terminology, statistical verification, intended use, functional testing and pharmaceutical requirements. It also introduces new annexes for break-loose and extrusion forces, residual volume, liquid leakage resistance and administration time.
What are the main changes?
Intended use plays a much greater role
Manufacturers must define the intended use of the finished prefilled syringe and consider factors such as:
- Medical indication and the criticality of administration
- Patient population, health status and user profile
- Route, site and frequency of administration
- Clinical or home-use environment
- Associated components or delivery devices
- Environmental conditions during transportation, storage and use
- Interactions between the user, syringe and surrounding environment
These considerations are expected to inform the test method. A syringe used by a healthcare professional for a routine clinical procedure may not require the same test conditions as an emergency product used by a patient or caregiver at home.
This allows testing to be more representative, but it also places greater responsibility on manufacturers to justify their methods and acceptance criteria through documented risk management.
Testing is more clearly focused on the finished system
Several requirements now explicitly call for testing the finished prefilled syringe in its intended-use configuration.
Depending on the product, this may mean testing with the intended drug formulation, plunger rod, needle, finger flange, backstop, safety device or needle-based injection system. Testing a component or an unrepresentative configuration may no longer provide enough evidence unless the manufacturer can demonstrate that subsequent processing and assembly do not affect the result.
This system-level approach is particularly relevant to pharmaceutical companies using platform components from multiple suppliers. Compliance data for the individual components remain valuable, but they do not remove the need to verify the final drug-device configuration.
Statistical expectations for design verification are clearer
The revision introduces a basic statistical approach for verifying functional performance requirements. The standard’s design-verification methods are intended to demonstrate performance at a 95% confidence level.
This should not be confused with routine manufacturing lot-release testing. ISO 11040-8 does not prescribe acceptable quality limits or universal lot-release sampling plans. Manufacturers still need product- and process-specific controls.
For development and quality teams, the change means reviewing whether sample sizes, confidence levels and acceptance criteria are adequately justified—not simply relying on a small number of pass/fail tests.
Break-loose and extrusion-force testing has been revised
Break-loose force is the force required to begin movement of the plunger stopper. Extrusion or glide force is the force required to continue moving it and deliver the syringe contents.
These characteristics can be affected by formulation viscosity, siliconization, stopper design, ageing, temperature, storage orientation and sterilization. They are also critical to usability and autoinjector compatibility.
The 2026 edition introduces a dedicated normative Annex A and clarifies that the finished syringe should be tested as intended for use. Guidance is more detailed around test setup, speed, data acquisition, measurement and reporting, helping reduce variation between laboratories.
Industry analysis also highlights a preferred data-acquisition rate of 500 Hz, intended-use-based test speeds and instructions to exclude the end-of-stroke force effect associated with expelling an air bubble from the reported extrusion force.
A new administration-time test has been added
A new Annex D describes a method for measuring administration time using a defined constant test force.
This is particularly relevant to high-viscosity biologics and products intended for manual self-administration or use in autoinjectors. A syringe may technically deliver its complete dose but still take too long—or require too much force—for the intended patient and use scenario.
Administration-time testing provides a more standardized way to evaluate the relationship between formulation viscosity, needle geometry, syringe dimensions, applied force and dose-delivery time. It can support both formal design verification and earlier platform-selection studies.
Because the annex is informative and the test is conditionally applicable, manufacturers should determine its relevance through intended-use analysis and risk management rather than assume that it is mandatory for every product.
Leakage and burst-resistance requirements have been reorganized
The former standalone subsection for burst resistance has been removed. Relevant content has been incorporated into the revised liquid-leakage-resistance requirements and a new normative Annex C.
This creates a more integrated approach to pressure integrity. Burst-resistance assessment is especially relevant when a prefilled syringe will experience elevated pressure inside a needle-based injection system.
Manufacturers should check whether existing protocols reflect the revised configurations, pressures, hold times and failure criteria rather than simply changing the standard number on a test report.
Other functional requirements have been clarified
The revision also updates or clarifies requirements for:
- Flange breakage resistance
- Front-end closure pull-off force and torque
- Connectivity with small-bore connectors
- Residual volume
- Needle penetration force
- Needle pull-out force
The requirement for front-end breakage resistance has been deleted. A new informative Annex B addresses residual-volume testing, while several other tests now include clearer methods or specification-limit expectations.
Unintended plunger-stopper movement is now addressed
A new requirement considers unintended stopper movement caused by factors such as pressure changes, temperature changes, phase transitions or assembly forces.
This is important for syringes with a gaseous headspace and for products exposed to altitude or pressure changes during shipping. Movement must not compromise the sterile barrier.
For global pharmaceutical supply chains, this change reinforces the link between transport conditions and container-closure performance. Distribution studies and altitude simulation may therefore need to feed more directly into the design-verification strategy.
How will the revision affect pharmaceutical customers?
For pharmaceutical and biotechnology companies, the main impact is likely to be a gap assessment rather than an immediate redesign of every prefilled-syringe product.
- Review the intended-use definition. Confirm that it covers the patient, user, route, environment, associated devices, transport conditions and criticality of administration.
- Map existing evidence to the revised clauses. Identify where current component data, development studies and design-verification reports already satisfy the new edition—and where additional evidence is required.
- Update test methods and SOPs. Pay particular attention to specimen configuration, test speed, data-acquisition settings, force calculations and reporting rules.
- Assess administration time. Determine whether the new method is relevant to the formulation, dose volume, delivery system and intended user.
- Revisit pressure and transport risks. Review leakage resistance, burst-related conditions and potential stopper movement during distribution.
- Reassess statistical justification. Confirm that design-verification sample sizes and acceptance criteria provide suitable confidence in product performance.
- Coordinate across functions and suppliers. Device engineering, formulation development, analytical teams, quality, regulatory affairs, component suppliers and contract laboratories may all hold part of the required evidence.
Some laboratories may be able to implement the revision mainly through method and software changes. Others may need load-control capability for administration-time testing, updated fixtures or new studies using the complete commercial configuration.
Key Takeaways
ISO 11040-8:2026 moves prefilled-syringe testing further toward an intended-use-driven, system-level model.
The revision recognizes that syringe performance cannot be separated from the formulation, patient, environment and delivery system. For pharmaceutical companies, compliance will depend less on completing a generic checklist and more on demonstrating that the chosen tests represent how the finished product will actually be transported, stored and used.
Organizations that begin with a structured gap assessment can identify where existing evidence remains valid, where test methods require updating and where targeted supplemental studies are needed. The objective is not simply to reference the latest edition of the standard—it is to build stronger evidence that the finished prefilled syringe will protect the medicine and deliver the intended dose safely and reliably.